BioAtla (BCAB) Short Interest Ratio & Short Volume

Short interest is the volume of BioAtla shares that have been sold short but have not yet been closed out or covered. As of November 15th, traders have sold 4,120,000 shares of BCAB short. Learn More on BioAtla's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCAB shares currently have a short interest ratio of 12.0. Learn More on BioAtla's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioAtla: Group One Trading L.P., Belvedere Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

BioAtla saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,120,000 shares, an increase of 1.0% from the previous total of 4,080,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioAtla: Jasper Therapeutics, Inc. (2.30%), Athira Pharma, Inc. (1.38%), Atara Biotherapeutics, Inc. (8.01%), Cidara Therapeutics, Inc. (1.36%), Ikena Oncology, Inc. (3.99%), Cardiol Therapeutics Inc. (0.41%), AVROBIO, Inc. (2.52%), C4 Therapeutics, Inc. (4.65%), aTyr Pharma, Inc. (0.32%), Cardiff Oncology, Inc. (3.58%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($7.24 billion), T-Mobile US, Inc. ($4.02 billion), Charter Communications, Inc. ($3.72 billion), Occidental Petroleum Co. ($2.80 billion), Lululemon Athletica Inc. ($2.48 billion), Coinbase Global, Inc. ($2.38 billion), Tractor Supply ($2.35 billion), Rivian Automotive, Inc. ($1.79 billion), Royal Caribbean Cruises Ltd. ($1.73 billion), and Moderna, Inc. ($1.71 billion). View all of the most shorted stocks.

Short selling BCAB is an investing strategy that aims to generate trading profit from BioAtla as its price is falling. BCAB shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for BioAtla occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCAB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCAB, twice per month. The most recent reporting period available is November, 15 2023.